Eli Lilly executive on crucial tirzepatide data: "It is a very exciting time"

Before the turn of the year, Eli Lilly will receive the phase III results for the drug tirzepatide, meant to beat the best products in the top-selling GLP-1 segment on the diabetes market. Jamie Croaning, who leads the development of the drug at Eli Lilly, speaks of a paradigm shift.
The US pharmaceutical company Eli Lilly is Novo Nordisk's greatest competitor on the diabetes market.
The US pharmaceutical company Eli Lilly is Novo Nordisk's greatest competitor on the diabetes market.
BY KEVIN GRØNNNEMANN, TRANSLATED BY NIELSINE NIELSEN

Before New Year's, the bar will be raised for how well a diabetes drug can perform when Eli Lilly displays the first phase III results from the future hope tirzepatide.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading